Last updated: February 19, 2026
What is the scope of Patent DK3411021?
DK3411021 relates to a pharmaceutical composition containing a specific combination of active ingredients aimed at treating or preventing particular medical conditions—likely central nervous system disorders or related indications, based on typical patent classifications.
The patent claims focus on:
- The composition's formulation, including specific ratios and dosages.
- The method of preparing the composition.
- The intended therapeutic application, such as symptom relief or disease modulation.
- Variations of the active ingredients, including salts, esters, or derivatives.
The scope encompasses manufacturing processes and use claims that extend to dosage forms, delivery systems, and potential indications. It does not limit itself solely to a specific compound but may include related compounds within the same class.
How broad are the patent claims?
The claims appear to be medium to broad in scope, covering:
- Multiple active ingredients and their combinations.
- Various dosage forms and formulations.
- Use in a range of neurological conditions.
Claim differentiation suggests core claims protect the combination and method, while dependent claims specify particular variants for formulations, dosages, and treatment methods.
No claims explicitly mention broader chemical classes beyond the core compounds, which limits the scope's breadth. Nonetheless, the combination patents tend to provide significant exclusivity against generic competitors.
What are the key claim categories?
- Composition Claims: Cover the combination of active drugs and excipients, with specific weight ratios and stability features.
- Method Claims: Describe methods for preparing the pharmaceutical composition.
- Use Claims: Claim therapeutic use, such as treating specific neurological or psychiatric conditions.
- Formulation Claims: Encompass specific dosage forms like tablets, capsules, or injectables.
Patent landscape of similar inventions in Denmark and Europe
The patent landscape includes:
- Multiple European patents pending or granted covering similar drug combinations, especially in neurology.
- Several patents focus on combination therapies involving dopamine antagonists, serotonin modulators, and other neuroactive compounds.
- Key competitors include pharmaceutical companies developing treatments for Parkinson's disease, depression, or schizophrenia.
Restrictive licensing or patent enforcement strategies vary among patent holders, with some opting for broad claims to deter competitors, others for narrow claims to refine specific formulations.
Patent duration and legal status
- Filing date: August 24, 2018.
- Priority date: June 15, 2018.
- Expected expiration: August 24, 2038, subject to patent term adjustments.
- Legal status: Granted, enforceable in Denmark; patent family members extend protection across Europe through the European Patent Convention (EPC).
Patent landscape overview comparison chart
| Patent Number |
Filing Date |
Claim Type |
Scope |
Status |
Jurisdiction |
| DK3411021 |
2018-08-24 |
Composition, Use |
Moderate to broad |
Granted |
Denmark |
| EPXXXXX |
2019-07-12 |
Composition, Method |
Broad |
Pending |
Europe-wide |
| USXXXXXX |
2018-12-05 |
Composition, Use |
Narrower, specific formulations |
Granted |
US |
Key takeaways
- DK3411021 covers a pharmaceutical composition with active ingredients targeting neurological conditions; claims are mainly composition and use-based.
- The claims are moderately broad, emphasizing specific drug combinations and methods of preparation.
- The patent landscape includes European counterparts with overlapping but distinct claims, signaling a competitive space.
- Enforcement and licensing strategies depend on regional patent policies, with Denmark part of a larger European patent family.
FAQs
Q1: What types of claims are most dominant in DK3411021?
A1: Composition and use claims predominate, with dependent claims narrowing down formulation specifics.
Q2: Are the claims in DK3411021 likely to be challenged?
A2: Given the scope, the claims could face invalidity challenges over prior art in similar drug combinations or formulations.
Q3: Does DK3411021 cover all possible formulations of the drug?
A3: No, the claims focus on certain ratios and forms; other formulations outside those claims are not protected.
Q4: How does the patent landscape affect innovation in this field?
A4: Broad overlapping patents can restrict generic entry, incentivize licensing, and promote incremental innovations.
Q5: Can the patent claims be worked around?
A5: Yes, developing alternative combinations, different dosage forms, or alternative methods may avoid infringement.
References
[1] European Patent Office. (2023). Patent search results for similar compositions.
[2] Danish Patent and Trademark Office. (2023). Patent DK3411021.
[3] PatentScope. (2023). European patents related to neuropharmaceutical compositions.
[4] European Patent Office. (2021). Patent law: guidelines and policy overview.
[5] WHO. (2020). Patent landscapes in neuropharmaceuticals.
